中国两种灭活新冠疫苗替换接种的安全性、免疫原性与免疫持久性:一项观察性队列研究
为应对WIBP-CorV新冠疫苗全国短缺,中国监管机构批准以BBIBP-CorV完成以WIBP-CorV起始的初级免疫程序。本观察性队列研究比较了WIBP-CorV后接BBIBP-CorV与两剂BBIBP-CorV的免疫原性和安全性。两方案均有免疫原性,接种后两个月内免疫原性无显著差异,安全性均可接受。
要点
- 观察组275人、对照组133人,第二剂均接种BBIBP-CorV。
- 接种后1个月两组中和抗体血清阳性率分别为98.91%和99.25%,6个月分别为53.16%和70.69%。
- 两组不良反应率分别为11.27%和18.80%,均为轻中度。
核心结论
- 两种初级免疫程序均有免疫原性;WIBP-CorV后接BBIBP-CorV的免疫原性在接种后两个月内与两剂BBIBP-CorV无显著差异;两种方案的安全性均可接受。
- BBIBP-CorV可用于完成以WIBP-CorV起始的初级免疫程序。
研究设计与样本
- 观察性队列研究,纳入18-59岁健康成人,第一剂已接种WIBP-CorV或BBIBP-CorV者分别进入观察组和对照组,第二剂均接种BBIBP-CorV。
- 观察组275人,对照组133人,纳入时间为2021年3月至12月。
- 第二剂接种后1、2、6个月采集血清,用SARS-CoV-2株HB01经微量中和细胞病变效应法测定中和抗体滴度,以WHO抗SARS-CoV-2免疫球蛋白国际标准品标准化。
- 第二剂接种后7天内评估安全性。
主要发现
- 中和抗体血清阳性率(≥1:4):观察组1个月为98.91%、6个月为53.16%;对照组1个月为99.25%、6个月为70.69%。
- 1个月几何平均滴度:观察组21.33,对照组22.45;1个月几何平均浓度:观察组227.71 IU/mL,对照组273.27 IU/mL。
- 接种后1至2个月,观察组血清阳性率和滴度与对照组无显著差异。
- 不良反应率:观察组11.27%,对照组18.80%,所有不良反应均为轻中度。
临床怎么用
- BBIBP-CorV可用于完成以WIBP-CorV起始的初级免疫程序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To mitigate a national shortage of WIBP-CorV COVID-19 vaccine, China's regulator approved administering BBIBP-CorV after WIBP-CorV for completion of a primary series. In a pragmatic observational study, we compared immunogenicity and safety of a primary series of WIBP-CorV followed by BBIBP-CorV with a primary series of two doses of BBIBP-CorV. METHODS: We invited healthy 18-59-years-old adults who had already received either WIBP-CorV or BBIBP-CorV as their first dose in a primary series to participate in this observational cohort study. Subjects who had received WIBP-CorV as their first dose became the observation group; subjects who had received BBIBP-CorV as their first dose became the control group. All participants received BBIBP-CorV as their second dose. We obtained sera 1, 2, and 6 months after second doses for nAb titer measurement by micro-neutralization cytopathic effect assay with SARS-CoV-2 strain HB01, standardized with WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Safety was assessed for the 7 days after administration of second doses. RESULTS: Between March and December 2021, 275 subjects were included in the observation group and 133 in the control group. Neutralizing seropositivity (≥1:4) rates were 98.91 % and 99.25 % at 1 month and 53.16 % and 70.69 % at 6 months. One-month geometric mean titers (GMTs) were 21.33 and 22.45; one-month geometric mean concentrations (GMCs) were 227.71 IU/mL and 273.27 IU/mL. One to two months after vaccination, observation group seropositivity rates and titers were not significantly different to the control group's. Adverse reaction rates were 11.27 % and 18.80 %, all mild or moderate in severity. CONCLUSIONS: Both primary series were immunogenic; immunogenicity of WIBP-CorV followed by BBIBP-CorV was not different than immunogenicity following two doses of BBIBP-CorV for two months after vaccination; safety profiles were acceptable for both regimens. BBIBP-CorV can be used to complete a primary series that started with WIBP-CorV.
引用
- Wang X, Deng Y, Zhao L, et al. Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort study. Vaccine. 2022. PMID: 36031501. doi:10.1016/j.vaccine.2022.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。